You're watching...
Ariad Pharmaceuticals CEO Harvey Berger on the strong results for the company’s new leukemia drug and the other drugs in the pipeline the company is...
Also in this playlist...
Auto-advance: ON
Auto-advance
This transcript is automatically generated
Do you guys wish you had a stock in a company whose shares have soared.
70%.
Over the past year alone.
How about more than 30% just year to date well that might not be too late ARIAD Pharmaceuticals has been on quite the terror.
It has some very promising drugs in the pipeline doctor Harvey Berger is the founder chairman and CEO who had very -- news out this week regarding here.
Drug that is for chronic mile Lloyd said get cancer either leukemia drug into -- -- happening -- which is this drug.
Showed some very positive signs but now where does it go from here.
Well thanks very much -- so what we have presented earlier this week -- the results of the late stage pivotal trial.
Four -- that did it showed very striking results.
In patients who really had no other options and that you know form of leukemia.
That when it advances through this stage patients really our our -- have very limited steps.
But our next step is to a file for approval in the US as well as in Europe we expect to have and that will be available for patients.
In the US by early next year in Europe later next year so really available for patients on a broad spectrum now.
To have a cost yet for this there.
No not yet I mean will come to that later this year as we work through the indications.
And you know how the drug is going to be.
Described.
Two physicians.
Both here in the US as well as in Europe well we'll get there later this.
-- -- -- patients who took this saw a reduction in abnormal cell growth -- that's exactly right over half of the patients early in treatment.
Already had rather profound the facts.
And what's so striking is you know how important drug could be.
To patients with leukemia.
-- moderator of bars session.
I'm at the meeting early this week described it as -- -- -- revolutionizing.
On the treatment of CM now really a major new drug.
That you can't -- -- -- you have the wind there but with your bone cancer drug that you were right on that did not get approval and you're partnering with Merck on that right.
What happens next is that just yet after all these years of trying to develop this or does it go somewhere from.
And not at all I mean it's very important -- is very strongly committed.
To moving rid of -- -- -- -- forward.
They are planning and initiating trials son in breast cancer.
In various forms of lung cancer as well as some other cancers.
Where that -- state trials have been very positive and -- -- -- in the focus from bone cancer Iraq other -- exactly do that.
No proper outlet for.
We can shift from one cancer to the other based on the clinical data.
What else is in the pipeline right now and with which partners.
Well going for it -- no partners we're doing everything ourselves where with and that they -- going to commercialize the drug worldwide.
On around where even going into Japan and we're gonna start clinical trials on to that have been Japan may in the near term.
The -- next in line is our new lung cancer drug AP 113.
We're going to be presenting the first clinical results for this drug.
At a major oncology meeting in Europe in this September we believe it's really two drugs in one.
Two forms of lung cancer both treated with a single new targeted drug I'm.
Looking at your stock.
'cause we we talk about both that I real medical advancements that -- people's lives but also us from perhaps I think that save somebody's portfolio which are 70%.
Over the past year important point out we always like to do this for our viewers.
There is significant short position on this ten nearly 10% of the float is being -- -- that's very common I want people to know for.
Up and coming pharmaceutical companies or drug developers because.
They they take a chance that you will have some bad news in there will be some type of drop in the stock in the moment.
What do you say to anybody who believes of this this company is not really for real and can't really.
-- -- well I think the clinical data are compelling.
Our strategy going it alone worldwide is compelling that's the way to build real shareholder value you have the money to do that we do have the money do it we're going forward and will deliver that towards shareholders doctor Harvey Berger founder chairman and CEO of areas pharmaceuticals thank you for telling us your story -- -- we wanna -- -- please come back.
